NCT01868529View on ClinicalTrials.gov

Comparison of Insulin Degludec With Insulin Glargine in Subjects With Type 1 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
DiabetesDiabetes Mellitus, Type 1
Interventions
DRUG

insulin degludec

Once daily dosing administered subcutaneously (s.c., under the skin) followed by a clamp visit. The two treatment periods will be separated by a wash-out period where the subjects will resume their normal insulin treatment.

DRUG

insulin glargine

Once daily dosing administered subcutaneously (s.c., under the skin) followed by a clamp visit. The two treatment periods will be separated by a wash-out period where the subjects will resume their normal insulin treatment.

Trial Locations (1)

41460

Neuss

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY